Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McGAW GOING TO KENDALL MANAGEMENT IN $ 960 MIL. LEVERAGED BUYOUT

Executive Summary

McGAW GOING TO KENDALL MANAGEMENT IN $ 960 MIL. LEVERAGED BUYOUT co-financed by New York investment firm Clayton & Dubilier. The Kendall management group is being led by President and CEO Dale Sherratt. Under the purchase agreement, a new company formed by Clayton & Dubilier and the Kendall management will acquire from Colgate Kendall's worldwide hospital supply business, and the Kendall-McGaw intravenous solution business, Kendall-Futuro home health care businesses, Respiratory Care pulmonary therapy business, Polyken specialty adhesives business, and the U.S. Curity/Curad consumer adhesives line. Sales for the group were approximately $ 850 mil. in 1987. The agreement values Kendall at approximately $ 1.1 bil., according to Colgate. The sale price of $ 960 mil. reflects an agreement that Colgate will retain "certain financial and business assets including real estate in various locations and some overseas non-healthcare consumer products businesses" which are part of the Kendall operation, the company said. The leveraged buyout offer is worth 10 times the hospital products business' expected 1988 operating income. Industry sources project 1988 revenues of $ 950 mil. for the Kendall group, with operating profit of $ 95 mil. Colgate will use the more than $ 700 mil. in after-tax proceeds from the sale to reduce debt and to "develop and acquire consumer product businesses." The transaction is expected to net Colgate over $ 200 mil. in after-tax income. Colgate will receive $ 910 mil. in cash and $ 50 mil. in debentures for Kendall. The sale is expected to close in the fourth quarter. Colgate announced its intention to sell Kendall and exit the professional healthcare business in late April. The firm has run a health subsidiary since 1972. The transaction is the largest leveraged buyout handled thus far by Clayton & Dubilier. The private investment firm currently manages a pool of approximately $ 300 mil. in institutional capital for investment in management buyouts. Since it was formed in 1978, the company has participated in more than 12 acquisitions, including, in the past two years, the purchase of the Uniroyal Goodrich Tire Company and the Oklahoma Division of Safeway Stores. An indicator of the market's current interest in health care LBOs is the number of medical LBO funds which have been springing up lately. Ex-J&J exec David Collins is heading a new $ 100 mil. management buyout fund, Galen Partners, in cooperation with New York City health care consulting firm, The Wilkerson Group. At a Sept. 15 symposium in New York, Wilkerson President John Wilkerson said that investment banking firm Robertson, Colman & Stephens has established a $ 60-$ 70 mil. medical LBO fund, and that Alex. Brown is in the process of forming its own fund.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel